Shreya C. Pal - Search Results

Year	Number of Results
2022	8
2023	7
2024	0

1

Pal SC, Méndez-Sánchez N. Pal SC, et al. Ther Adv Endocrinol Metab. 2023 Jan 21;14:20420188221145650. doi: 10.1177/20420188221145650. eCollection 2023. Ther Adv Endocrinol Metab. 2023. PMID: 36699945 Free PMC article. Review.

2

Editorial: Acute Hepatitis of Unknown Origin in Children. Is Autoimmunity at Play?

Mendez-Sanchez N, Pal SC. Mendez-Sanchez N, et al. Among authors: pal sc. Med Sci Monit. 2022 Jun 4;28:e937371. doi: 10.12659/MSM.937371. Med Sci Monit. 2022. PMID: 35707853 Free PMC article.

3

Nonalcoholic Fatty Liver Disease in Latin America and Australia.

Castellanos-Fernandez MI, Pal SC, Arrese M, Arab JP, George J, Méndez-Sánchez N. Castellanos-Fernandez MI, et al. Among authors: pal sc. Clin Liver Dis. 2023 May;27(2):301-315. doi: 10.1016/j.cld.2023.01.015. Epub 2023 Feb 26. Clin Liver Dis. 2023. PMID: 37024209 Review.

4

Detangling the interrelations between MAFLD, insulin resistance, and key hormones.

Pal SC, Eslam M, Mendez-Sanchez N. Pal SC, et al. Hormones (Athens). 2022 Dec;21(4):573-589. doi: 10.1007/s42000-022-00391-w. Epub 2022 Aug 3. Hormones (Athens). 2022. PMID: 35921046 Review.

5

Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis.

Pal SC, Méndez-Sánchez N. Pal SC, et al. World J Gastroenterol. 2023 Jul 7;29(25):3999-4008. doi: 10.3748/wjg.v29.i25.3999. World J Gastroenterol. 2023. PMID: 37476582 Free PMC article. Review.

6

Editorial: Treatment with Dual Incretin Receptor Agonists to Maintain Normal Glucose Levels May Also Maintain Normal Weight and Control Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).

Ordóñez-Vázquez AL, Beltrán-Gall SM, Pal SC, Méndez-Sánchez N. Ordóñez-Vázquez AL, et al. Among authors: pal sc. Med Sci Monit. 2022 Sep 12;28:e938365. doi: 10.12659/MSM.938365. Med Sci Monit. 2022. PMID: 36093924 Free PMC article.

7

MAFLD: perceived stigma-a single-center Mexican patient survey.

Méndez-Sánchez N, Pal SC, Fassio E, Díaz-Ferrer J, Prado-Robles JA. Méndez-Sánchez N, et al. Among authors: pal sc. Hepatol Int. 2023 Apr;17(2):507-508. doi: 10.1007/s12072-022-10448-y. Epub 2022 Dec 6. Hepatol Int. 2023. PMID: 36474091 No abstract available.

8

How far are we from an approved drug for nonalcoholic steatohepatitis?

Méndez-Sánchez N, Pal SC, Córdova-Gallardo J. Méndez-Sánchez N, et al. Among authors: pal sc. Expert Opin Pharmacother. 2023 Jun;24(9):1021-1038. doi: 10.1080/14656566.2023.2206953. Epub 2023 May 1. Expert Opin Pharmacother. 2023. PMID: 37092896

9

New terms for fatty liver disease other than MAFLD: Time for a reality check.

Méndez-Sánchez N, Pal SC. Méndez-Sánchez N, et al. Among authors: pal sc. J Hepatol. 2022 Dec;77(6):1716-1717. doi: 10.1016/j.jhep.2022.08.009. Epub 2022 Aug 18. J Hepatol. 2022. PMID: 35988685 No abstract available.

10

Correction to: Detangling the interrelations between MAFLD, insulin resistance, and key hormones.

Pal SC, Eslam M, Mendez-Sanchez N. Pal SC, et al. Hormones (Athens). 2022 Dec;21(4):759. doi: 10.1007/s42000-022-00395-6. Hormones (Athens). 2022. PMID: 36031645 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

13 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year